Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study.
Min Jee KimYe-Jee KimDae Hyun JeongSeon Ok KimSeokchan HongSang Hyoung ParkKyung Wook JoPublished in: Therapeutic advances in gastroenterology (2024)
In Korean patients with IBD, non-anti-TNF biologics (vedolizumab/ustekinumab) tended to be associated with a lower risk of serious infection or active tuberculosis than anti-TNF-α agents.